Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases

Toshiyoshi Fujiwara, Kenichi Sakagami, Junji Matsuoka, Shigehiro Shiozaki, Susumu Uchida, Keiji Fujioka, Yoshihiro Takada, Tadashi Onoda, Kunzo Orita

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We evaluated the antitumor effect of an interleukin 2 (IL-2) slow delivery system, the IL-2 minipellet, using a murine hepatic metastasis model. The IL-2 minipellet consists of atelocollagen derived from natural bovine skin together with 1 × 106 units of recombinant IL-2. Administration of the IL-2 minipellet was performed into the spleens of BALB/c mice after translocation of the spleens to the s.c. position. Administration produced detectable serum IL-2 levels for 72 h. The IL-2 minipellet was evaluated for its efficacy against hepatic metastases from colon 26 adenocarcinoma in the BALB/c mice. Both the administration of the IL-2 minipellet alone and its combination with the injection of 5 × 107 lymphokine-activated killer cells resulted in significant reductions of the number of metastatic nodules. Moreover, increased survival of mice bearing colon 26 adenocarcinoma was noted in these two treatment groups. To investigate the mechanism of the IL-2 minipellet activity, we tested the lytic potential of splenocytes obtained after administration of the IL-2 minipellet in a 51Cr release assay. Cytotoxicity against YAC-1 cells and colon 26 cells was significantly augmented on Day 2 after minipellet administration. These results demonstrated that local administration of the IL-2 minipellet into the hepatic circulation was extremely effective against metastatic liver cancer.

Original languageEnglish
Pages (from-to)7003-7007
Number of pages5
JournalCancer Research
Volume50
Issue number21
Publication statusPublished - Nov 1 1990

Fingerprint

Immunotherapy
Interleukin-2
Colon
Adenocarcinoma
Neoplasm Metastasis
Liver
Spleen
Liver Circulation
Lymphokine-Activated Killer Cells
Liver Neoplasms
Skin
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases. / Fujiwara, Toshiyoshi; Sakagami, Kenichi; Matsuoka, Junji; Shiozaki, Shigehiro; Uchida, Susumu; Fujioka, Keiji; Takada, Yoshihiro; Onoda, Tadashi; Orita, Kunzo.

In: Cancer Research, Vol. 50, No. 21, 01.11.1990, p. 7003-7007.

Research output: Contribution to journalArticle

Fujiwara, T, Sakagami, K, Matsuoka, J, Shiozaki, S, Uchida, S, Fujioka, K, Takada, Y, Onoda, T & Orita, K 1990, 'Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases', Cancer Research, vol. 50, no. 21, pp. 7003-7007.
Fujiwara, Toshiyoshi ; Sakagami, Kenichi ; Matsuoka, Junji ; Shiozaki, Shigehiro ; Uchida, Susumu ; Fujioka, Keiji ; Takada, Yoshihiro ; Onoda, Tadashi ; Orita, Kunzo. / Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases. In: Cancer Research. 1990 ; Vol. 50, No. 21. pp. 7003-7007.
@article{1225210810b843f39d299f14dceb1b59,
title = "Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases",
abstract = "We evaluated the antitumor effect of an interleukin 2 (IL-2) slow delivery system, the IL-2 minipellet, using a murine hepatic metastasis model. The IL-2 minipellet consists of atelocollagen derived from natural bovine skin together with 1 × 106 units of recombinant IL-2. Administration of the IL-2 minipellet was performed into the spleens of BALB/c mice after translocation of the spleens to the s.c. position. Administration produced detectable serum IL-2 levels for 72 h. The IL-2 minipellet was evaluated for its efficacy against hepatic metastases from colon 26 adenocarcinoma in the BALB/c mice. Both the administration of the IL-2 minipellet alone and its combination with the injection of 5 × 107 lymphokine-activated killer cells resulted in significant reductions of the number of metastatic nodules. Moreover, increased survival of mice bearing colon 26 adenocarcinoma was noted in these two treatment groups. To investigate the mechanism of the IL-2 minipellet activity, we tested the lytic potential of splenocytes obtained after administration of the IL-2 minipellet in a 51Cr release assay. Cytotoxicity against YAC-1 cells and colon 26 cells was significantly augmented on Day 2 after minipellet administration. These results demonstrated that local administration of the IL-2 minipellet into the hepatic circulation was extremely effective against metastatic liver cancer.",
author = "Toshiyoshi Fujiwara and Kenichi Sakagami and Junji Matsuoka and Shigehiro Shiozaki and Susumu Uchida and Keiji Fujioka and Yoshihiro Takada and Tadashi Onoda and Kunzo Orita",
year = "1990",
month = "11",
day = "1",
language = "English",
volume = "50",
pages = "7003--7007",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases

AU - Fujiwara, Toshiyoshi

AU - Sakagami, Kenichi

AU - Matsuoka, Junji

AU - Shiozaki, Shigehiro

AU - Uchida, Susumu

AU - Fujioka, Keiji

AU - Takada, Yoshihiro

AU - Onoda, Tadashi

AU - Orita, Kunzo

PY - 1990/11/1

Y1 - 1990/11/1

N2 - We evaluated the antitumor effect of an interleukin 2 (IL-2) slow delivery system, the IL-2 minipellet, using a murine hepatic metastasis model. The IL-2 minipellet consists of atelocollagen derived from natural bovine skin together with 1 × 106 units of recombinant IL-2. Administration of the IL-2 minipellet was performed into the spleens of BALB/c mice after translocation of the spleens to the s.c. position. Administration produced detectable serum IL-2 levels for 72 h. The IL-2 minipellet was evaluated for its efficacy against hepatic metastases from colon 26 adenocarcinoma in the BALB/c mice. Both the administration of the IL-2 minipellet alone and its combination with the injection of 5 × 107 lymphokine-activated killer cells resulted in significant reductions of the number of metastatic nodules. Moreover, increased survival of mice bearing colon 26 adenocarcinoma was noted in these two treatment groups. To investigate the mechanism of the IL-2 minipellet activity, we tested the lytic potential of splenocytes obtained after administration of the IL-2 minipellet in a 51Cr release assay. Cytotoxicity against YAC-1 cells and colon 26 cells was significantly augmented on Day 2 after minipellet administration. These results demonstrated that local administration of the IL-2 minipellet into the hepatic circulation was extremely effective against metastatic liver cancer.

AB - We evaluated the antitumor effect of an interleukin 2 (IL-2) slow delivery system, the IL-2 minipellet, using a murine hepatic metastasis model. The IL-2 minipellet consists of atelocollagen derived from natural bovine skin together with 1 × 106 units of recombinant IL-2. Administration of the IL-2 minipellet was performed into the spleens of BALB/c mice after translocation of the spleens to the s.c. position. Administration produced detectable serum IL-2 levels for 72 h. The IL-2 minipellet was evaluated for its efficacy against hepatic metastases from colon 26 adenocarcinoma in the BALB/c mice. Both the administration of the IL-2 minipellet alone and its combination with the injection of 5 × 107 lymphokine-activated killer cells resulted in significant reductions of the number of metastatic nodules. Moreover, increased survival of mice bearing colon 26 adenocarcinoma was noted in these two treatment groups. To investigate the mechanism of the IL-2 minipellet activity, we tested the lytic potential of splenocytes obtained after administration of the IL-2 minipellet in a 51Cr release assay. Cytotoxicity against YAC-1 cells and colon 26 cells was significantly augmented on Day 2 after minipellet administration. These results demonstrated that local administration of the IL-2 minipellet into the hepatic circulation was extremely effective against metastatic liver cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025151829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025151829&partnerID=8YFLogxK

M3 - Article

C2 - 2208166

AN - SCOPUS:0025151829

VL - 50

SP - 7003

EP - 7007

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -